Casirivimab + Imdevimab is primarily used to manage mild to moderate COVID-19 in adults and pediatric patients who have tested positive for the SARS-CoV-2 virus and are at a high risk of progressing to severe illness, including hospitalization or death. This medicine belongs to the class of monoclonal antibodies.
It is also used in individuals aged 65 and older or those with chronic conditions that increase their risk of severe COVID-19.
Infusion-related reactions (fever, chills, nausea, and headache)
Bronchospasm
Hypotension
Throat irritation
Rash
Casirivimab + Imdevimab is a combination of two monoclonal antibodies primarily used for the treatment of mild to moderate COVID-19 in patients at high risk of progression to severe disease.
These antibodies work by binding to the spike protein of the SARS-CoV-2 virus, preventing it from attaching to the ACE2 receptors on human cells, thereby inhibiting viral entry. By neutralizing the virus and enhancing the immune response, this combination can effectively limit viral replication and reduce the risk of severe disease
BDS, MDS
BMS, FMC, MD Resident
Casirivimab + Imdevimab are available for administration through two primary routes: intravenous infusion and subcutaneous injection, which are administered in a hospital setting under the guidance of a doctor.
Casirivimab + Imdevimab is intended for use in adults and pediatric patients who are 12 years of age and older and weigh at least 40 kg.
There are no specific contraindications for Casirivimab + Imdevimab under normal conditions.
Casirivimab + Imdevimab may interact with other monoclonal antibodies (such as tocilizumab, and sarilumab), immunosuppressants (like corticosteroids, tacrolimus), and live attenuated vaccines (such as MMR). These interactions may affect the immune response and the effectiveness of treatment.
In the event of an overdose of Casirivimab + Imdevimab, medical attention should be sought immediately, as the specific effects can vary and serious adverse reactions including anaphylaxis may occur.
If a dose of Casirivimab + Imdevimab is missed, it should be administered as soon as possible when remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to avoid potential overdose.
Most side effects are temporary and generally harmless and resolve when discontinuing this medicine. However, if you experience any severe side effects or worsening of any of the symptoms, please consult your doctor.
For infusion-related reactions such as fever or chills during IV administration, pausing or slowing the infusion rate may help manage these symptoms.
For injection site reactions such as redness or swelling from SC injections, applying a cold compress to the site after administration may provide relief.
Casirivimab + Imdevimab doesn't specifically impair driving or machinery use. However, if you feel dizzy after taking it, avoid these activities until the symptoms pass.
It is advisable to consult your doctor regarding its use during these conditions.
Patients with severe allergies or hypersensitivity to any component of this medication should exercise caution.
Given that anaphylactic reactions have been observed with its use, it should be administered in settings where immediate treatment for severe reactions is available.
While taking Casirivimab + Imdevimab for COVID-19 management, maintaining a healthy lifestyle is crucial. This includes a balanced diet rich in fruits, vegetables, and lean proteins to support immune function.
Staying hydrated by drinking plenty of water can help manage mild side effects such as headaches or dizziness.
Ensuring adequate rest and avoiding excessive physical exertion can help your body focus on fighting off the infection.
Practicing stress-reducing activities such as meditation or light yoga might also aid in overall well-being during treatment with this medication.
Frequently asked questions
No, Casirivimab + Imdevimab is not a steroid. It is a combination of two monoclonal antibodies designed to block the virus' attachment and entry into human cells.
Casirivimab + Imdevimab is not known to directly affect sleep. However, some people may experience side effects like fatigue, which could potentially influence sleep patterns. If you notice any unusual changes in your sleep while taking this combination, it's best to consult your doctor.
There is no current evidence or data to suggest that Casirivimab + Imdevimab has an impact on fertility. If you have concerns about fertility, it is advised to consult your doctor.
There are no specific diet restrictions while taking Casirivimab + Imdevimab. However, maintaining a balanced and nutritious diet can support your overall health during treatment. If you have any concerns or underlying conditions, consult your doctor for personalized advice.
Casirivimab + Imdevimab is not usually administered daily but as per the doctor's instructions based on the severity of the patient's condition and their response to treatment.
The time taken for Casirivimab + Imdevimab to work can vary depending on several factors, including the severity of the infection and the individual patient's response to treatment.
The timing of administration of this medication is based on the doctor's recommendation.
Subscribe
Claim your complimentary health and fitness tips subscription and stay updated on our newest promotions.
Download Truemeds
Manage your health with ease Download Truemeds today!Get easy access to medicine refills, health information, and more. With our app, you'll never have to wait in line again. Download now and start taking control of your health.
Contact Us
Our customer representative team is available 7 days a week from 9 am - 9 pm.
v3.4.16
Our Payment Partners